Effects of Recombinant LH in Patients With Repeated Implantation Failure
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Pregnancy rates fall dramatically in women after 35 years undergoing to IVF or ICSI. While
ovarian aging obviously plays the major role in this phenomenon, over suppression of
endogenous LH concentrations with GnRH agonists or antagonists-an integral part of standard
IVF/ ICSI protocols-may also play a pivotal role.
Assisted reproduction technology protocols using GnRH agonists have been considered as the
standard protocol during the last two decades, but the use of GnRH antagonists offers the
opportunity to control the endogenous LH surge in a rapid and more convenient way.
LH plays a key role in the intermediate-late phases of folliculogenesis. The presence of
receptors for LH in cumulus granulosa cells and its correlation with oocyte maturation has
been demonstrated. Although ovarian stimulation is efficiently achieved in most cases by the
administration of exogenous FSH alone, specific subgroups of women may benefit from LH
activity supplementation during ovarian stimulation. Some authors have found improved outcome
with LH activity supplementation in advanced reproductive age women.
LH has a number of roles in follicular development, induction of ovulation, completion of
meiosis I, early luteinization and the production of progesterone.
The efficacy of recombinant human follicle-stimulating hormone (r-hFSH) for ovarian
stimulation is well established however, the role of supplementary recombinant human
luteinizing hormone (r-hLH) is less clear.
Aim of the present study is to evaluate If adding rLH in the late phase of stimulation can
benefit in some patient awith repeated implantation failure.